Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Acosta

Showing results (321-330 of 338) with videos related to

Pageof 34
Sort By:
Plos Neglected Tropical Diseases|November 21, 2012
A novel procedure for precise quantification of Schistosoma japonicum eggs in bovine fecesBin Xu, Catherine A Gordon, Wei Hu, et al.
AIDS (London, England)|November 30, 2020
Pharmacokinetics and safety of maraviroc in neonatesJulia C Rosebush, Brookie M Best, Ellen G Chadwick, et al.
JAMA|August 15, 2006
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialRoy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, et al.
The New England Journal of Medicine|April 30, 2004
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionRoy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, et al.
Journal of the Pediatric Infectious Diseases Society|September 26, 2015
A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus SepsisMark J Abzug, Marian G Michaels, Ellen Wald, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
The Journal of Infectious Diseases|December 12, 2012
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin, Edward P Acosta, Mark N Prichard, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|September 24, 2021
The unexplored role of sedentary time and physical activity in glucose and lipid metabolism-related placental mRNAs in pregnant women who are obese: the DALI lifestyle randomised controlled trialP Acosta-Manzano, B Leopold-Posch, D Simmons, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
Pageof 34

Showing results (321-330 of 338) with videos related to

Sort By:
Pageof 34
Plos Neglected Tropical Diseases|November 21, 2012
A novel procedure for precise quantification of Schistosoma japonicum eggs in bovine fecesBin Xu, Catherine A Gordon, Wei Hu, et al.
AIDS (London, England)|November 30, 2020
Pharmacokinetics and safety of maraviroc in neonatesJulia C Rosebush, Brookie M Best, Ellen G Chadwick, et al.
JAMA|August 15, 2006
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialRoy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, et al.
The New England Journal of Medicine|April 30, 2004
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionRoy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, et al.
Journal of the Pediatric Infectious Diseases Society|September 26, 2015
A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus SepsisMark J Abzug, Marian G Michaels, Ellen Wald, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
The Journal of Infectious Diseases|December 12, 2012
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin, Edward P Acosta, Mark N Prichard, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|September 24, 2021
The unexplored role of sedentary time and physical activity in glucose and lipid metabolism-related placental mRNAs in pregnant women who are obese: the DALI lifestyle randomised controlled trialP Acosta-Manzano, B Leopold-Posch, D Simmons, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
Pageof 34